Cargando…

S154: IDENTIFICATION OF NOVEL FACTORS CONTROLLING NON GENETIC CELL PLASTICITY IN CHRONIC MYELOID LEUKEMIA

Detalles Bibliográficos
Autores principales:	Baselli, Guido, Alekseenko, Alisa, Brinkman, Eva, Pareja-Sanchez, Yerma, Sinanis, Lefteris, Pelechano, Vicent
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Oral Sessions
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428473/ http://dx.doi.org/10.1097/01.HS9.0000967528.08711.d7

Ejemplares similares

Differential regulation of mRNA stability modulates transcriptional memory and facilitates environmental adaptation
por: Li, Bingnan, et al.
Publicado: (2023)

S106: METABOLIC PLASTICITY REVEALS A TARGETABLE VULNERABILITY IN LEUKEMIA
por: Andrieu, Guillaume, et al.
Publicado: (2023)

S126: IL-9 SECRETED BY LEUKEMIA STEM CELLS INDUCES THE EPIGENETIC ACTIVATION OF BM-INFILTRATING CD4+ T CELLS IN ACUTE MYELOID LEUKEMIA
por: Radpour, Ramin, et al.
Publicado: (2023)

S116: CELLULAR AND MOLECULAR MECHANISMS OF EVI1-EXPRESSING MLL-REARRANGED ACUTE MYELOID LEUKEMIA
por: Châtel-Soulet, Hugues-Etienne, et al.
Publicado: (2022)

S156: FRONTLINE ASCIMINIB COMBINATION IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS. THE FASCINATION TRIAL.
por: Ernst, Thomas, et al.
Publicado: (2023)

S131: CLINICAL IMPLICATIONS OF SECONDARY-AML TYPE MUTATIONS IN PATIENTS WITH DE NOVO ACUTE MYELOID LEUKEMIA
por: Sun, K., et al.
Publicado: (2022)

OPUSeq simplifies detection of low-frequency DNA variants and uncovers fragmentase-associated artifacts
por: Alekseenko, Alisa, et al.
Publicado: (2022)

S120: MNX1-ACTIVATING ENHANCER HIJACKING EVENTS IN ACUTE MYELOID LEUKEMIA WITH DELETIONS ON CHROMOSOME 7Q
por: Riedel, Anna, et al.
Publicado: (2023)

S138: VALIDATION OF THE REVISED 2022 EUROPEAN LEUKEMIANET (ELN) RISK STRATIFICATION IN ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA
por: Bill, Marius, et al.
Publicado: (2023)

S153: MECHANISMS OF TROMBOGENESIS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA UNDER TREATMENT WITH PONATINIB AND OTHER TYROSINE KINASE INHIBITORS
por: José Cuenca Zamora, Ernesto, et al.
Publicado: (2023)

S143: NATURAL CLONAL EVOLUTION OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH BIMODAL CD49D EXPRESSION REVEALS CD49D PLASTICITY
por: Tissino, Erika, et al.
Publicado: (2023)

S123: ACUTE MYELOID LEUKEMIA STEM CELL SUBTYPES DEFINED BY MUTATIONS AND DIFFERENTIATION STATE REGULATE APOPTOTIC DEPENDENCY AND CLINICAL RESPONSE TO VENETOCLAX.
por: Waclawiczek, Alexander, et al.
Publicado: (2023)

S159: HEALTH-RELATED QUALITY OF LIFE OF PATIENTS WITH CHRONIC MYELOID LEUKEMIA AFTER DISCONTINUATION OF TYROSINE KINASE INHIBITORS: RESULTS FROM THE EURO-SKI STUDY
por: Efficace, Fabio, et al.
Publicado: (2023)

S129: ADOPTIVELY INFUSED MEMORY-LIKE (ML) NATURAL KILLER (NK) CELLS ELICIT ADAPTIVE IMMUNE RESPONSES IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML)
por: Rutella, Sergio, et al.
Publicado: (2023)

S310: VENETOCLAX PLUS AZACITIDINE DELAYS DETERIORATION OF HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA: VIALE-A LONG-TERM FOLLOW UP
por: Pratz, Keith, et al.
Publicado: (2023)

S127: DELTATP73 IMPOSES TP53 MUTANT-LIKE PHENOTYPES INCLUDING DRUG RESISTANCE AND POOR PROGNOSIS ON TP53-WILD TYPE ACUTE MYELOID LEUKEMIA.
por: Pereira-Martins, Diego A, et al.
Publicado: (2023)

S135: NEXT-GENERATION SEQUENCING-BASED MEASURABLE RESIDUAL DISEASE MONITORING IN ACUTE MYELOID LEUKEMIA WITH FLT3 INTERNAL TANDEM DUPLICATION TREATED WITH INTENSIVE CHEMOTHERAPY PLUS MIDOSTAURIN
por: Rücker, Frank G, et al.
Publicado: (2023)

S132: TOLERABILITY AND EFFICACY OF THE FIRST-IN-CLASS ANTI-CD47 ANTIBODY MAGROLIMAB COMBINED WITH AZACITIDINE IN FRONTLINE PATIENTS WITH TP53-MUTATED ACUTE MYELOID LEUKEMIA: PHASE 1B RESULTS
por: Daver, N. G., et al.
Publicado: (2022)

S137: IMPACT OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN FIRST COMPLETE REMISSION PLUS FLT3 INHIBITION WITH QUIZARTINIB IN ACUTE MYELOID LEUKEMIA WITH FLT3-ITD: RESULTS FROM QUANTUM-FIRST
por: Schlenk, Richard, et al.
Publicado: (2023)

S157: NILOTINIB VS. NILOTINIB + PEG-INTERFERON ΑLPHA INDUCTION AND NILOTINIB OR PEG-INTERFERON ΑLPHA MAINTENANCE THERAPY FOR NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA PATIENTS. THE TIGER TRIAL.
por: Hochhaus, Andreas, et al.
Publicado: (2023)

S121: MULTIPARAMETER PREDICTION OF MYELOID NEOPLASIA RISK
por: Gu, Muxin, et al.
Publicado: (2023)

S150: TIMING AND CLONAL TRAJECTORY TO CHRONIC MYELOID LEUKAEMIA DRIVEN BY THE PHILADELPHIA CHROMOSOME
por: Kamizela, Aleksandra, et al.
Publicado: (2023)

Direct detection of SARS-CoV-2 using non-commercial RT-LAMP reagents on heat-inactivated samples
por: Alekseenko, Alisa, et al.
Publicado: (2021)

S308: RISK FACTORS FOR VENOUS THROMBOEMBOLISM IN ACUTE PROMYELOCYTIC LEUKEMIA
por: Sabljic, Nikica, et al.
Publicado: (2023)

S122: MUTANT IDH1 HIJACKS DIFFERENTIATION PROGRAMS IN MYELOID PROGENITOR CELLS TO IMPAIR GRANULOCYTIC DIFFERENTIATION.
por: Hakobyan, Mariam, et al.
Publicado: (2023)

S145: VENETOCLAX-OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 6-YEAR RESULTS OF THE RANDOMIZED CLL14 STUDY
por: Al-Sawaf, Othman, et al.
Publicado: (2023)

S263: CYTOPENIAS, AGE AND CAR-HEMATOTOX SCORE PREDICT THE DEVELOPMENT OF POST CAR T-CELL THERAPY-RELATED MYELOID NEOPLASMS
por: Gurney, Mark, et al.
Publicado: (2023)

S116: DONOR-DERIVED CD5 CAR T CELLS FOR T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
por: Pan, Jing, et al.
Publicado: (2023)

S105: CLONAL DIFFERENTIATION TRAJECTORIES OF ADULT ACUTE LYMPHOBLASTIC LEUKEMIA AT SINGLE CELL LEVEL
por: Geßner, Alec, et al.
Publicado: (2023)

S160: GATA2B HAPLOINSUFFICIENCY CAUSES ABERRANT TRANSCRIPTIONAL REGULATORY SIGNATURES IN HSPCS RESULTING IN MYELOID AND ERYTHROID DYSPLASIA IN ZEBRAFISH
por: Zhang, Wei, et al.
Publicado: (2023)

S158: EFFICACY OF LOW-DOSE TYROSINE KINASE INHIBITOR THERAPY AFTER ACHIEVING MAJOR MOLECULAR RESPONSE IN PERSONS WITH CHRONIC MYELOID LEUKAEMIA
por: LI, Zongru, et al.
Publicado: (2023)

S124: PHOSPHOPROTEOMICS ACCURATELY PREDICTS RESPONSES TO MIDOSTAURIN PLUS CHEMOTHERAPY IN TWO INDEPENDENT COHORTS OF FLT3 MUTANT-POSITIVE ACUTE MYELOID LEUKAEMIA
por: Dokal, Arran, et al.
Publicado: (2023)

S151: COMBINATION OF LARGE SPLEEN AND LOW IN VIVO KINASE INHIBITION IS AN EARLY PREDICTOR OF INFERIOR MOLECULAR RESPONSE AND POOR OUTCOMES IN CHRONIC MYELOID LEUKAEMIA
por: Kok, Chung, et al.
Publicado: (2023)

S155: PROGNOSTIC FACTORS FOR 3-YEAR MAJOR MOLECULAR RESPONSE MAINTENANCE IN CHRONIC MYELOID LEUKAEMIA PATIENTS IN THE EUROPEAN STOP KINASE INHIBITORS (EURO-SKI) TRIAL
por: Pfirrmann, Markus, et al.
Publicado: (2023)

S174: MYELOID NGS ANALYSES OF PAIRED SAMPLES FROM BONE MARROW AND PERIPHERAL BLOOD YIELD CONCORDANT RESULTS: A PROSPECTIVE COHORT ANALYSIS OF THE AGMT STUDY GROUP
por: Pleyer, Lisa, et al.
Publicado: (2023)

S112: THE EFFECT OF IMMUNOGLOBULIN PROPHYLAXIS ON INFECTIOUS MORBIDITY IN PEDIATRIC PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA: RESULTS OF A RANDOMIZED CONTROLLED TRIAL
por: Thus, Kirsten, et al.
Publicado: (2023)

S206: ONCO-FETAL REPROGRAMMING DRIVES HIGH-RISK JUVENILE MYELOMONOCYTIC LEUKEMIA, WHICH CAN BE TARGETED BY ANTI-CD52 TREATMENT
por: Hartmann, Mark, et al.
Publicado: (2023)

P1489: HIGH DOSE IRON IMPAIRS MALIGNANT B-CELL VIABILITY AND IMPROVES IMMUNE ANTITUMOR FUNCTIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA
por: Bordini, Jessica, et al.
Publicado: (2023)

S131: A RANDOMISED ASSESSMENT OF THE SEQUENTIAL ADDITION OF THE KINASE INHIBITOR QUIZARTINIB TO INTENSIVE CHEMOTHERAPY IN OLDER ACUTE MYELOID LEUKAEMIA (AML) PATIENTS: RESULTS FROM THE NCRI AML18 TRIAL
por: Knapper, Steven, et al.
Publicado: (2023)

Chromatin-sensitive cryptic promoters putatively drive expression of alternative protein isoforms in yeast
por: Wei, Wu, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_70soofur6r22mhrm3fkojl15se